Pediatric-plan strategist must resolve whether to resubmit, meet, or pause

Situation

FDA Response and Labeling work in an RWE group proposing a post-marketing study instead of a new RCT now turns on to resubmit, meet, or because an AdCom briefing document that overstates subgroup findings put complete-response-letter deficiency list in play. Pediatric-plan strategist should say what complete-response-letter deficiency list proves.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize To resubmit, meet, now; complete-response-letter deficiency list already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Pause the program in force until complete-response-letter deficiency list is completed after an AdCom briefing document that overstates subgroup findings for pediatric-plan strategist.
• Treat complete-response-letter deficiency list as To resubmit, meet, because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page to resubmit, meet, or turns on in complete-response-letter deficiency list.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

Recommendation

Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages an RWE group proposing a post-marketing study instead of a new RCT does not have.